Cholelithiasis

There are 39 papers on cholelithiasis in aging research: 24 observational studies in people, 14 reviews. The newest story, Nov 7, 2026: “Two drug classes linked to fewer heart failure flare-ups”.

Disease

39 papers study it7 more mention it18 findings

MeSH

6 new papers in 30 daysSee all 46 papers on cholelithiasis

“and cholelithiasis (RR = 1.67; 95%CI: 1.14-2.44; I2 = 0%, P = 0.95)”
Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysisJournal of diabetes investigation2024doi:10.1111/jdi.14340
  • Humans24

Interventions

4

Cholesterol-lowering medication

no changein humans1

1 study
  1. Cholesterol-lowering medication was not clearly linked with cholelithiasis in humans (β = 0.0060; p = 0.631).

    HumansGenetic liability to medication use; multivariable Mendelian randomization adjusted for LDL-C, HDL-C, and triglycerides; conditional F-statistics < 10 and marked heterogeneity

More on Cholesterol-lowering medication

Simvastatin

no changein humans1

1 study
  1. Simvastatin was not clearly linked with cholelithiasis in humans (β = 0.0051; p = 0.858).

    HumansGenetic liability to medication use; multivariable Mendelian randomization adjusted for LDL-C, HDL-C, and triglycerides; conditional F-statistics < 10 and marked heterogeneity

More on Simvastatin

Exenatide

upin humans1

1 study
  1. Exenatide is linked with higher cholelithiasis in humans (reporting relative to semaglutide reference, FAERS disproportionality) (PRR 1.33 (95% CI 1.23–1.44), p<0.001).

    Humansreporting relative to semaglutide reference, FAERS disproportionality

More on Exenatide

DPP-4 inhibitors

no changein humans1RR 1

1 study
  1. DPP-4 inhibitors showed no clear effect on cholelithiasis in patients with type 2 diabetes (RR 1.00 [95% CI 0.76-1.32]).

    Reviewin patients with type 2 diabetes

More on DPP-4 inhibitors

Effects

1

Lean mass

no changein humans1

1 study
  1. Cholelithiasis was not clearly linked with lean mass in humans.

    Humans

More on Lean mass

Associations

11

GLP-1 receptor agonists

downin humans2upin humans1HR 0.92

3 studies
  1. GLP-1 receptor agonists are linked with a lower risk of cholelithiasis in humans (Obesity and type 2 diabetes; compared with DPP-4 inhibitors) (1.02% vs. 1.16%; HR 0.92, 95% CI 0.87–0.96).

    HumansObesity and type 2 diabetes; compared with DPP-4 inhibitors1 yearn = 281,283

  2. GLP-1 receptor agonists are associated with cholelithiasis in humans (type 2 diabetes or obesity) (OR 1.11).

    Humanstype 2 diabetes or obesity5 yearsn = 721,898

  3. GLP-1 receptor agonists are linked with a lower risk of cholelithiasis in humans (propensity-matched women with breast cancer and type 2 diabetes).

    Humanspropensity-matched women with breast cancer and type 2 diabeteswithin 5 years of index datefemalesn = 19,608

More on GLP-1 receptor agonists

Type 2 diabetes

upin humans1OR 1.14

1 study
  1. Cholelithiasis is associated with type 2 diabetes in humans (Compared with gallstone-free controls) (OR = 1.14).

    HumansCompared with gallstone-free controlsn = 419,250

More on Type 2 diabetes

Cholesterol-lowering medication

downin humans1

1 study
  1. Cholesterol-lowering medication is associated with cholelithiasis in humans (Genetic correlation of medication-use liability) (rg = −0.223; p = 2.47 × 10−3).

    HumansGenetic correlation of medication-use liability

More on Cholesterol-lowering medication

Simvastatin

downin humans1

1 study
  1. Simvastatin is associated with cholelithiasis in humans (Genetic correlation of medication-use liability) (rg = −0.277; p = 1.54 × 10−4).

    HumansGenetic correlation of medication-use liability

More on Simvastatin

Semaglutide

upin humans1HR 1.11

1 study
  1. Semaglutide is linked with a higher risk of cholelithiasis in humans (Obesity and type 2 diabetes; compared with tirzepatide) (HR 1.11, 95% CI 1.05–1.18).

    HumansObesity and type 2 diabetes; compared with tirzepatide1 yearn = 242,876

More on Semaglutide

Ondansetron

upin humans1HR 1.501

1 study
  1. Ondansetron is linked with a higher risk of cholelithiasis in humans (concurrent with semaglutide initiation; ondansetron within 30 days of initiation) (HR 1.501 (95% CI 1.299–1.734)).

    Humansconcurrent with semaglutide initiation; ondansetron within 30 days of initiation12 monthsn = 33,152

More on Ondansetron

Age-related macular degeneration

downin humans1

1 study
  1. Cholelithiasis is linked with a lower risk of age-related macular degeneration in humans (aHR = 0.72, 95% CI: 0.69-0.75, P < 0.0001).

    Humans

More on Age-related macular degeneration

Tirzepatide

upin humans1RR 1.67

1 study
  1. Tirzepatide raises the risk of cholelithiasis in humans (RR 1.67; 95% CI 1.14–2.44).

    Human trialn = 12,351

More on Tirzepatide

Muscle mass

downin humans1OR 0.81

1 study
  1. Muscle mass is linked with a lower risk of cholelithiasis in humans (OR 0.81, p < .001).

    Humans

More on Muscle mass

Metabolic dysfunction-associated steatotic liver disease

upin humans1OR 1.171

1 study
  1. Metabolic dysfunction-associated steatotic liver disease is linked with a higher risk of cholelithiasis in humans (Genetically proxied NAFLD using chronically elevated alanine transaminase levels) (OR 1.171, 95% CI 1.083–1.266).

    HumansGenetically proxied NAFLD using chronically elevated alanine transaminase levels

More on Metabolic dysfunction-associated steatotic liver disease

All 11

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 1Mar 2026: 4Apr 2026: 1May 2026: 0Jun 2026: 1Jul 2026: 5Aug 2026: 0Sep 2026: 1Oct 2026: 5Nov 2026: 223 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Two drug classes linked to fewer heart failure flare-ups

Heart failure flare-ups had a hazard ratio—a relative risk measure—of 0.69 over one year with added drugs versus standard care alone.Heart failure flare-ups had a hazard ratio—a relative risk measure—of 0.69 over one year with added drugs versus standard care alone.

Cohort studyInterventions

See all 46 papers on cholelithiasis